


WHAT IS CLAIMED IS:

1. A compound represented by Formula I:



5 wherein R¹, R², R³ are independently chosen from hydrogen or an alkyl group;
R⁴ is H or OR¹;
R⁵ is OCON(R¹,R²), OCOR¹, or OR⁷;
R⁶ is H, OR⁷, CONR¹R², CH₂OR⁷, CO₂R¹R², N(R¹R²), with the proviso that both R⁵
and R⁶ are not H;
10 Aryl is at least one aryl group;
A is chosen from hydrogen, an alkyl group, C(=O)OR⁷, OR⁷, CR⁷, C(=O)NR¹R²,
SO₂(NR¹R²), halogen, or CF₃; and
R⁷ is H, a substituted or unsubstituted alkyl group, C₁₋₃CONR¹R², C₁₋₃N(R¹R²),
C₁₋₃CO₂H, or C₁₋₃CO₂C₁₋₃alkyl.

15

2. The compound of claim 1, wherein R¹, R², R³ are independently chosen from
hydrogen H or C₁₋₃ alkyl;
R⁴ is H or OR¹;
R⁵ is OCON(R¹,R²), OCOR¹, or OR⁷;
20 R⁶ is H, OR⁷, CONR¹R², CH₂OR⁷, CO₂R¹R², N(R¹R²), with the proviso that both
R⁵ and R⁶ are not H;
Aryl is phenyl, pyridinyl, or thienyl;
A is chosen from hydrogen, C₁₋₄alkyl, C(=O)OR⁷, OR⁷, CR⁷, C(=O)NR¹R²,
SO₂(NR¹R²), halogen, or CF₃;
25 R⁷ is H, C₁₋₃alkyl, C₁₋₃CONR¹R², C₁₋₃N(R¹R²), C₁₋₃CO₂H, C₁₋₃CO₂C₁₋₃alkyl
C₁₋₃alkyl substituted with hydroxyl, C₁₋₃CO₂C₁₋₃alkyl, C₁₋₃CON(C₁₋₃alkyl)₂,

C(=NH)NH₂, NHC(=NH)NH₂, or C₁₋₃alkoxy.

3. A method of controlling normal or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one compound of claim 1.

4. The method of claim 3, wherein R¹, R², R³ are independently chosen from hydrogen H or C₁₋₃alkyl;

R⁴ is H or OR¹;

R⁵ is OCON(R¹,R²), OCOR¹, or OR⁷;

10 R⁶ is H, OR⁷, CONR¹R², CH₂OR⁷, CO₂R¹R², N(R¹R²), with the proviso that both R⁵ and R⁶ are not H;

Aryl is phenyl, pyridinyl, or thienyl;

A is chosen from hydrogen, C₁₋₄alkyl, C(=O)OR⁷; OR⁷, CR⁷, C(=O)NR¹R², SO₂(NR¹R²), halogen, or CF₃;

15 R⁷ is H, C₁₋₃alkyl, C₁₋₃CONR¹R², C₁₋₃N(R¹R²), C₁₋₃CO₂H, C₁₋₃CO₂C₁₋₃alkyl C₁₋₃alkyl substituted with hydroxyl, C₁₋₃CO₂C₁₋₃alkyl, C₁₋₃CON(C₁₋₃alkyl)₂, C(=NH)NH₂, NHC(=NH)NH₂, or C₁₋₃alkoxy.

5. A method for the treatment of glaucoma comprising administering a pharmaceutically effective amount of a composition comprising at least one compound of claim 1.

20 6. The method of claim 5, wherein R¹, R², R³ are independently chosen from hydrogen H or C₁₋₃alkyl;

R⁴ is H or OR¹;

R⁵ is OCON(R¹,R²), OCOR¹, or OR⁷;

25 R⁶ is H, OR⁷, CONR¹R², CH₂OR⁷, CO₂R¹R², N(R¹R²), with the proviso that both R⁵ and R⁶ are not H;

Aryl is phenyl, pyridinyl, or thienyl;

A is chosen from hydrogen, C₁₋₄alkyl, C(=O)OR⁷; OR⁷, CR⁷, C(=O)NR¹R², SO₂(NR¹R²), halogen, or CF₃;

-30-

R^7 is H, $C_{1-3}alkyl$, $C_{1-3}CONR^1R^2$, $C_{1-3}N(R^1R^2)$, $C_{1-3}CO_2H$, $C_{1-3}CO_2C_{1-3}alkyl$ $C_{1-3}alkyl$ substituted with hydroxyl, $C_{1-3}CO_2C_{1-3}alkyl$, $C_{1-3}CON(C_{1-3}alkyl)_2$, $C(=NH)NH_2$, $NHC(=NH)NH_2$, or $C_{1-3}alkoxy$.

5 7. A pharmaceutical composition comprising the compound of claim 1 and at least one carrier.

8. A method to block or bind to serotonin receptors comprising administering an effective amount of at least one compound of claim 1 to a patient.